L
L. Tian
Publications - 16
Citations - 76
L. Tian is an academic researcher. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 4, co-authored 16 publications receiving 76 citations.
Papers
More filters
Journal ArticleDOI
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
TL;DR: In this paper , the profiles and mechanisms of NK cell homing and trafficking at steady state and during tumor development are summarized, aiming to improve NK cell-based cancer immunotherapy.
Journal ArticleDOI
ILC1s Control Leukemia Stem Cell Fate and Limit Development of AML
Zhenlong Li,Ruiz Benito Ma,Shoubao Ma,L. Tian,Ting-wei Lu,Jianying Zhang,Bethany L. Mundy-Bosse,Bin Amber Zhang,Guido Marcucci,Michael A. Caligiuri,Jianhua Yu +10 more
TL;DR: In this paper , the authors show that a high density of ILC1s induces leukemia stem cell (LSC) apoptosis in mice, while a lower density prevents LSCs from differentiating into leukemia progenitors and promotes their differentiation into non-leukemic cells, thus blocking the production of terminal myeloid blasts.
Journal ArticleDOI
Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19
Ting-wei Lu,Ruiz Benito Ma,Wenjuan Dong,Kun-Yu Teng,Daniel S. Kollath,Zhi-Ying Li,Jinhee Yi,Christian Bustillos,Shoubao Ma,L. Tian,Anthony Mansour,Zhenlong Li,Erik W. Settles,Jianying Zhang,Paul Keim,Bridget M. Barker,Michael A. Caligiuri,Jianhua Yu +17 more
TL;DR: In this article , a chimeric antigen receptor (CAR) consisting of an extracellular domain of ACE2 was used to target the spike protein of SARS-CoV-2.
Journal ArticleDOI
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity
L. Tian,Bo Xu,Yuqing Chen,Zhenlong Li,Jing Wang,Jianying Zhang,Ruiz Benito Ma,Shuai Cao,E. Antonio Chiocca,Balveen Kaur,Michael A. Caligiuri,Jianhua Yu +11 more
TL;DR: In this article , an oncolytic herpes simplex virus type 1 (oHSV) expressing a secretable single-chain variable fragment of the epidermal growth factor receptor (EGFR) antibody cetuximab linked to CCL5 was generated by an Fc knob-into-hole strategy that produces heterodimers.
Journal ArticleDOI
Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
Jia Feng,Haichan Xu,Andrew Cinquina,Zehua Wu,Wenli Zhang,Lihua Sun,Qi Chen,L. Tian,L. Song,Kevin G. Pinz,Masayuki Wada,Xun Jiang,William M Hanes,Yupo Ma,Hongyu Zhang +14 more
TL;DR: The results suggest that CD4-IL15/IL15sushi CAR T cells may be a safe and effective treatment for patients with relapsed or refractory T-cell lymphomas, where new treatment options are needed.